Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 8/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10488550 | 0.84 | ERN1 (0.40) | ERN1TDP1LMNAMEN1KMT2A | |
| SCHEMBL6413875 | 0.80 | CYP2A6 (0.40) | ERN1LMNACYP2A6MAPTHTT | |
| SCHEMBL4866312 | 0.78 | TDP1 (0.48) | ERN1TDP1LMNAMEN1KMT2A | |
| SCHEMBL2996328 | 0.78 | ERN1 (0.45) | ERN1TDP1LMNAMEN1KMT2A | |
| SCHEMBL31141573 | 0.78 | ERN1 (0.45) | ERN1TDP1LMNAMEN1KMT2A | |
| SCHEMBL3676494 | 0.78 | ERN1 (0.45) | ERN1TDP1LMNAMEN1KMT2A | |
| SCHEMBL29953557 | 0.78 | ERN1 (0.45) | ERN1TDP1LMNAMEN1KMT2A | |
| SCHEMBL6582354 | 0.77 | CYP2A6 (0.38) | ERN1TDP1LMNAMEN1KMT2A | |
| SCHEMBL419485 | 0.77 | ERN1 (0.51) | ERN1TDP1LMNAMEN1KMT2A | |
| SCHEMBL29388348 | 0.77 | ERN1 (0.51) | ERN1TDP1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2203161-B1 | QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | UNIV INDIANA RES & TECH CORP (US) | 2018-05-09 | — | — | EP | disclosed |
| US-9089605-B2 | Quinone derivatives, pharmaceutical compositions, and uses thereof | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-07-28 | — | — | US | disclosed |
| US-20100297113-A1 | QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2010-11-25 | — | — | US | disclosed |
| EP-2203161-A1 | QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Indiana University Research and Technology Corporation (US) | 2010-07-07 | — | — | EP | disclosed |
| EP-1753739-B1 | IMIDAZOL-2-ONE COMPOUNDS USEFUL IN THE TREATMENT OF VARIOUS DISORDERS | GLAXO GROUP LTD (GB) | 2010-04-28 | — | — | EP | disclosed |
| CN-100534983-C | Cyclic amine derivatives, processes for their preparation, and pharmaceutical compositions containing them | GLAXO GROUP LTD (GB) | 2009-09-02 | — | — | CN | disclosed |
| US-20090192194-A1 | Cyclic Amine Derivatives, Processes For Their Preparation, And Pharmaceutical Compositions Containing Them | ALVARO GIUSEPPE | 2009-07-30 | — | — | US | disclosed |
| US-7534893-B2 | Imidazol-2-one compounds useful in the treatment of various disorders | GLAXO GROUP LIMITED (GB) | 2009-05-19 | — | — | US | disclosed |
| WO-2009042544-A1 | QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2009-04-02 | — | — | WO | disclosed |
| US-20080262041-A1 | Beta-Lactams for Treatment of Cns Disorders | GLAXO GROUP LIMITED (GB) | 2008-10-23 | — | — | US | disclosed |
| EP-1169320-B1 | FARNESYL TRANSFERASE INHIBITORS HAVING A PYRROLE STRUCTURE AND PROCESS FOR PREPARATION THEREOF | LG CHEM INVESTMENT LTD (KR) | 2004-09-22 | — | — | EP | disclosed |
| CN-1151148-C | farnesyl transferase inhibitor with pyrrole structure and preparation method thereof | LGCI��ʽ���� | 2004-05-26 | — | — | CN | disclosed |
| US-20040018956-A1 | Aporphine esters and their use in therapy | AXON BIOCHEMICALS B.V. (NL) | 2004-01-29 | — | — | US | disclosed |
| EP-1309553-A1 | NEW APORPHINE ESTERS AND THEIR USE IN THERAPY | Axon Biochemicals B.V. (NL) | 2003-05-14 | — | — | EP | disclosed |
| US-6511978-B1 | For treating cancer, restenosis, atherosclerosis or viral infections | LG LIFE SCIENCES, LTD. (KR) | 2003-01-28 | — | — | US | disclosed |
| EP-1169320-A4 | FARNESYL TRANSFERASE INHIBITORS HAVING A PYRROLE STRUCTURE AND PROCESS FOR PREPARATION THEREOF | LG CHEM INVESTMENT LTD (KR) | 2002-10-30 | — | — | EP | disclosed |
| CN-1346353-A | farnesyl transferase inhibitor with pyrrole structure and preparation method thereof | LG CHEMICAL LTD (KR) | 2002-04-24 | — | — | CN | disclosed |
| WO-2002014279-A1 | NEW APORPHINE ESTERS AND THEIR USE IN THERAPY | AXON BIOCHEMICALS B.V. (NL) | 2002-02-21 | — | — | WO | disclosed |
| EP-1169320-A1 | FARNESYL TRANSFERASE INHIBITORS HAVING A PYRROLE STRUCTURE AND PROCESS FOR PREPARATION THEREOF | LG Chem Investment, Ltd. (KR) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000064891-A1 | FARNESYL TRANSFERASE INHIBITORS HAVING A PYRROLE STRUCTURE AND PROCESS FOR PREPARATION THEREOF | LG CHEM INVESTMENT LTD. (KR) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262041-A1 | Beta-Lactams for Treatment of Cns Disorders | SLC7A1, TPH1, CHRNA10 | ERN1 2613/4885TDP1 1946/4885LMNA 4098/4885 |
| US-20090192194-A1 | Cyclic Amine Derivatives, Processes For Their Preparation, And Pharmaceutical Compositions Containing Them | SLC6A4, OPRL1, HCRTR1 | ERN1 3505/4885TDP1 3828/4885LMNA 4130/4885 |
| US-20100297113-A1 | QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | APEX1, NQO1, REV1 | ERN1 676/4885TDP1 118/4885LMNA 4347/4885 |
| US-20040018956-A1 | Aporphine esters and their use in therapy | PRLHR, LPXN, NPSR1 | ERN1 3761/4885TDP1 519/4885LMNA 1681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.